CRISPR Therapeutics AG CRSP
As ofNov 20, 2026, 1:26 PM EST
- YTD
- -24.03%
- 1 year
- -19.18%
5D -2.87 (-6.82%)
- Market cap
- 3.85B
- Revenue (ttm)
- 25.17M
- EPS (ttm)
- -4.73
- Shares out
- 97.00M
- Forward P/E
- -10.56
- YTD return
- -24.03%
- 1-year return
- -19.18%
- 50-day average
- 51.23
- 200-day average
- 52.36
- Enterprise value
- 2.41B
- Volume
- 1.29M
- Avg volume
- 1.73M
- Open
- 38.18
- Previous close
- 38.93
- Day's range
- 38.18 – 40.17
- 52-week range
- 38.18 – 63.45
- Beta
- 1.90
- Analysts
- Buy
- Price target
- 85.42 (+114.4%)
- Earnings date
- Feb 11, 2027
Key statistics
- Price / sales
- 150.02
- Price / book
- 2.29
- Revenue growth
- 1325.10%
- Free cash flow
- -215.40M
- Total cash
- 2.27B
- Total debt
- 779.83M
- Return on equity
- -25.60%
- Short % of float
- 20.28%
Fundamental scorecard
7 of 25 checks passed on CRSP’s reported financials
7of 25 checks passed
- Value 1 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 44.00
- Target (mean)
- 85.42
- Target (high)
- 291.00
- Strong buy4
- Buy9
- Hold10
- Sell0
- Strong sell0
Next earnings
Feb 11, 2027
Expected Feb 11, 2027. Consensus EPS estimate -1.18.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2027 | Dec 30, 2026 | -1.17 | — | — | — |
| Nov 2, 2026 | Sep 30, 2026 | -1.04 | -1.15 | -0.11 | -10.58% |
| Aug 3, 2026 | Jun 30, 2026 | -1.19 | -0.94 | +0.25 | +21.01% |
| May 4, 2026 | Mar 31, 2026 | -1.19 | -1.28 | -0.09 | -7.60% |
| Feb 12, 2026 | Dec 31, 2025 | -1.15 | -1.37 | -0.22 | -19.13% |
| Nov 10, 2025 | Sep 30, 2025 | -1.26 | -1.17 | +0.09 | +7.14% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | Citigroup | main | Buy | Buy |
| Nov 4, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Nov 3, 2026 | Needham | reit | Buy | Buy |
| Oct 15, 2026 | UBS | init | — | Neutral |
| Aug 31, 2026 | Citizens | reit | Market Outperform | Market Outperform |
| Aug 31, 2026 | Needham | reit | Buy | Buy |
About CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- Website
- crisprtx.com
News
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics Eyes Late-Stage Trials as Key Data and CASGEVY Demand Build
CRISPR Therapeutics Highlights Substantial Lipid Reductions with Investigational Gene Editing Therapy CRISPR Therapeutics Reports 65% ANGPTL3 And 63% Triglyceride Reductions With CTX310 In Phase 1b Trial For Severe Hypertriglyceridemia; Well Tolerated, With No Treatment-Related Serious Adverse Events And No Clinically Relevant Elevations In Liver Transaminases
Reported Sunday, CRISPR Therapeutics Reports 83% Of Systemic Sclerosis Patients Achieved rCRISS-25 Response At Month 3 With Zugo-Cel, As All Nine Myositis Patients Achieve Moderate Or Major TIS Response
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $90
Wells Fargo Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $70
CRISPR Therapeutics Q3 EPS $(1.15) Misses $(0.98) Estimate, Sales $12.669M Beat $10.495M Estimate
Your note
Sign in to keep a note on CRSP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEHBAHANI ALI | Director | Sale | Sep 16, 2026 | 16,666 |
| BRUNO JULIANNE | Chief Operating Officer | Sale | Mar 20, 2025 | 17,632 |
| GEORGE SIMEON J. | Director | Purchase | Jul 15, 2025 | 0 |
| GREENE JOHN THOMAS | Director | Purchase | Feb 25, 2025 | 7,000 |
| KASINGER JAMES R. | General Counsel | Sale | Oct 5, 2026 | 94,784 |
| KULKARNI SAMARTH | Chief Executive Officer | Sale | Oct 18, 2026 | 311,899 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK Investment Management, LLC | 10.37% | 10,056,844 | 391.51M | Sep 29, 2026 |
| Blackrock Inc. | 8.56% | 8,299,872 | 323.11M | Sep 29, 2026 |
| State Street Corporation | 5.15% | 4,994,047 | 194.42M | Sep 29, 2026 |
| Capital World Investors | 4.89% | 4,739,139 | 184.49M | Sep 29, 2026 |
| Orbis Allan Gray Ltd | 4.66% | 4,519,261 | 175.93M | Sep 29, 2026 |
| GSK plc | 2.69% | 2,608,419 | 101.55M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Trust-ARK Innovation ETF | 5.55% | 5,381,819 | 209.51M | Oct 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.80% | 2,716,415 | 105.75M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.40% | 2,325,509 | 90.53M | Sep 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 2.35% | 2,278,710 | 88.71M | Oct 30, 2026 |
| NEW PERSPECTIVE FUND | 2.00% | 1,944,073 | 75.68M | Sep 29, 2026 |
| SmallCap World Fund Inc | 1.75% | 1,694,327 | 65.96M | Sep 29, 2026 |
